National Cancer Center, Japan
21
10
11
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 21 trials
100.0%
+13.5% vs industry average
14%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
Role: collaborator
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
Role: lead
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
Role: collaborator
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Role: lead
NCCH2006/MK010 Trial (FORTUNE Trial)
Role: lead
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Role: lead
A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
Role: lead
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
Role: collaborator
A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
Role: lead
Asian Multicenter Prospective Study of ctDNA Sequencing
Role: lead
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
Role: lead
Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
Role: lead
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
Role: lead
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
Role: lead
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Role: lead
Accuracy for Predicting Deep Submucosal Invasion
Role: collaborator
International Prospective Registry on Local Treatment Approaches in MLS
Role: collaborator
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Role: collaborator
Revision of the EORTC QLQ-BN20 Questionnaire
Role: collaborator
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
Role: lead